On November 13, 2026, the Securities and Exchange Board of India (SEBI) executed one of the most consequential regulatory interventions in modern Indian capital markets—yet the vast majority of founders completely overlooked it. SEBI formally constituted an 18-member expert working group tasked with undertaking a comprehensive, ground-up overhaul of the Innovators Growth Platform (IGP) under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.
The leadership of this panel signals total institutional seriousness: it is co-chaired by Srini Srinivasan, Chairman of the Indian Venture and Alternate Capital Association (IVCA), and Prashanth Prakash, Partner at Accel Partners. Their mandate is singular: build a functional public listing bridge for research-intensive, pre-revenue, and early-commercialization technology enterprises.
Why is this an existential development for the startup ecosystem? Because India’s innovation economy is undergoing a massive tectonic evolution. We have graduated past consumer e-commerce, aggregators, and simple fintech apps. Today, India’s most ambitious founders are building in Deep-Tech, Biotechnology, Space Exploration, Semiconductor Design, Quantum Computing, and AI Hardware—enterprises that require three to five years of intensive research, patent prosecution, and capital expenditure before generating their first rupee of commercial revenue.
Under India’s traditional public listing architecture, an unprofitable, pre-revenue company is legally barred from listing on the Main Board of the NSE or BSE. And until now, the IGP framework was so rigid, illiquid, and compliance-heavy that it saw virtually zero market traction. If SEBI’s working group successfully resolves these structural bottlenecks, early-stage deep-tech startups will finally secure a sovereign domestic exit pathway—transforming how venture capitalists value and diligence Indian cap tables today.
The Macro Capital Squeeze: Why Deep-Tech Startups Need Public Markets
India officially boasts over 2,50,000 recognized startups under the Department for Promotion of Industry and Internal Trade (DPIIT), cementing its position as the world’s third-largest startup powerhouse. However, behind this macro milestone lies a severe capital bifurcation:
The Early-Stage Funding Reality
During the first nine months of 2026, seed-stage venture funding across Indian startups plummeted by 37% year-on-year. While dry powder remains abundant in domestic and global private equity funds, institutional capital is disproportionately fleeing toward safe, late-stage, cash-flow-positive businesses.
For a space-tech company engineering orbital launch vehicles, or a semiconductor venture developing silicon photonics chips, standard 10-year venture fund cycles are fundamentally mismatched. Without a public listing mechanism to refinance early venture rounds and unlock institutional retail capital, deep-tech founders face an excruciating choice: shut down, or execute complex cross-border corporate flips to Delaware or Singapore to pursue a future NASDAQ listing.
A modernized Innovators Growth Platform reverses this brain drain, allowing high-conviction Indian intellectual property to remain domiciled in India while tapping public market liquidity.
The Autopsy of Legacy IGP: Why the 2018 Framework Failed
Originally introduced in 2015 as the Institutional Trading Platform (ITP) and rebranded in 2019 as the Innovators Growth Platform, the regime was designed with noble intentions: enable technology startups without traditional track records of profitability to list on stock exchanges.
In practice, the framework proved virtually unworkable. In five years, fewer than a handful of companies even attempted an IGP listing. Four regulatory bottlenecks paralyzed adoption:
| Regulatory Bottleneck | The Legacy Rule Under SEBI ICDR | Why It Paralyzed Deep-Tech Startups |
|---|---|---|
| 1. Institutional Pre-Issue Capital | At least 25% of pre-issue capital had to be held by Qualified Institutional Buyers (QIBs) or Accredited Investors for at least 2 years. | Deep-tech companies funded by angel syndicates, founder bootstrapping, or government grants (BIRAC/iDEX) were instantly disqualified. |
| 2. Punitive Trading Lot Sizes | Minimum trading lot sizes were set artificially high (initially ₹10 Lakhs, later ₹2 Lakhs). | Completely choked secondary market liquidity; retail and high-net-worth investors were priced out, creating a dormant market. |
| 3. Prohibitive Compliance Drag | Post-listing governance was almost as onerous as the Main Board under SEBI (LODR) Regulations. | Pre-revenue companies with lean teams were crushed by quarterly disclosure burdens designed for mature corporate conglomerates. |
| 4. The Main Board Migration Wall | Onerous net worth and profitability conditions required to graduate from IGP to the Main Board. | Companies saw no point in listing on an illiquid junior board if migrating to the main exchange required years of regulatory hurdles. |
What SEBI’s 18-Member Working Group Is Actually Reviewing
The constitution of the November 2026 working group is not an incremental tweak; it represents a philosophical reconsideration of how early-stage capital formation functions in India. The panel’s terms of reference specifically address five structural frontiers:
1. Pre-Revenue & IP-Based Listing Eligibility
Should an enterprise with zero commercial revenue be allowed to list publicly if it possesses verified intellectual property, granted global patents, successful clinical trials, or defense prototype contracts? The working group is examining specialized quantitative valuation benchmarks that decouple listing eligibility from historical income statements.
2. Adapting Global Pre-Revenue Playbooks (NASDAQ & HKEX)
The panel is directly benchmarking international frameworks that successfully unlocked deep-tech listings:
- NASDAQ Biotechnology & Technology Tracks: Permitting companies to list based on global market capitalization, substantial public float, and accredited institutional sponsorship rather than operating earnings.
- Hong Kong Stock Exchange (HKEX) Chapter 18A & 18C: Celebrated global listing regimes for pre-revenue biotech companies and “Specialist Technology Companies” (spanning advanced materials, semiconductors, and green technology). Chapter 18C allows commercial-stage and pre-commercial specialist tech companies with significant R&D expenditures (30% to 50% of operating expenses) to list with tailored investor protections.
3. Modernizing Allocation and Pricing Mechanisms
Re-evaluating mandatory minimum subscription thresholds (historically 75% or 90%) and book-building pricing collars that penalize high-volatility, research-driven assets during turbulent macroeconomic windows.
4. Frictionless Graduation to the Main Board
Establishing clear, objective quantitative pathways for an IGP-listed enterprise to migrate seamlessly to the Main Board of the NSE or BSE once it crosses defined commercial revenue or profitability milestones, without requiring a secondary IPO filing.
The Founder’s Imperative: Why You Must Be IPO-Ready from Day 1
Many deep-tech founders operate under a dangerous illusion: “We are an R&D startup. We will worry about statutory compliance, cap table structuring, and board governance when we reach Series B or prepare for an investment bank.”
This mindset is fatal. If the Innovators Growth Platform establishes an operational public exit pathway within 24 to 36 months of founding, institutional venture funds will conduct public-market-grade due diligence on your cap table on Day 1.
The 4 Pillars of Day-1 Deep-Tech IPO Readiness
- 1. Ironclad Intellectual Property Assignment: 100% of codebase, algorithms, laboratory notebooks, and patent applications must be formally assigned from founders, university labs, and contractors to the corporate entity via stamped, registered IP Assignment Deeds.
- 2. Clean, Reconciled Capital Structure: Elimination of informal SAFE notes. All convertible capital must be issued as FEMA-compliant Compulsorily Convertible Preference Shares (CCPS) or iSAFEs, fully reconciled with MCA Form PAS-3 and the Form MGT-1 Register of Members.
- 3. Early Ind AS & R&D Capitalization Hygiene: Maintain audited financials compliant with Indian Accounting Standards (Ind AS). Explicitly adhere to Ind AS 38 (Intangible Assets), strictly segregating research phase expenses (charged to P&L) from development phase costs eligible for capitalization.
- 4. Institutional ESOP Governance: Legally registered Employee Stock Option Plans (ESOPs) with transparent vesting schedules, statutory board authorizations, and shareholder approvals that withstand SEBI SBEB (Share Based Employee Benefits) scrutiny.
Interactive Executive FAQ: SEBI Innovators Growth Platform & Deep-Tech IPOs
1. What is the Innovators Growth Platform (IGP) under SEBI regulations?
The Innovators Growth Platform (IGP) is a dedicated stock exchange listing platform established under Chapter X of the SEBI (ICDR) Regulations, 2018. It was designed to enable early-stage, technology-driven, and innovative startups that do not meet standard Main Board profitability or net worth criteria to list on Indian stock exchanges with tailored disclosure norms.
2. Why did SEBI constitute an 18-member working group on 13 November 2026?
SEBI formed the working group because the existing IGP framework experienced virtually zero adoption due to rigid institutional pre-issue holding mandates, excessive trading lot sizes, and onerous post-listing compliance. Co-chaired by leaders from IVCA and Accel, the panel is reviewing the framework to make public markets accessible for pre-revenue deep-tech, biotech, semiconductor, and space-tech ventures.
3. Can a company with zero commercial revenue list publicly in India today?
Under standard Main Board regulations (Regulation 6(1) of SEBI ICDR), a company must have minimum net tangible assets of ₹3 Crore, average operating profit of ₹15 Crore over three years, and net worth of ₹1 Crore. While Regulation 6(2) allows unprofitable companies to list if 75% of the issue is allocated to Qualified Institutional Buyers (QIBs), the process remains prohibitive for early-stage pre-revenue deep-tech companies. The IGP review specifically aims to unlock viable pre-revenue listing routes.
4. How do global exchanges like NASDAQ and HKEX accommodate pre-revenue technology listings?
NASDAQ provides specialized listing tiers based on global market capitalization, revenue run-rate, or accredited institutional sponsorship rather than profitability. The Hong Kong Stock Exchange operates Chapter 18A for pre-revenue biotech companies and Chapter 18C for Specialist Technology Companies, allowing public listings based on R&D expenditure ratios (30%–50%) and third-party investment verification.
5. Why is the 37% decline in seed funding in 2026 accelerating the need for an IGP overhaul?
Venture capital in 2026 has become increasingly risk-averse, concentrating capital into safe, cash-generating later-stage assets. Because deep-tech startups require 3 to 5 years of heavy capital expenditure before generating cash flows, the contraction in seed funding threatens to starve early innovation unless public market capital and institutional retail liquidity become accessible.
6. What is the danger of using informal US SAFE notes for an Indian deep-tech startup planning to list?
Under Indian foreign exchange law (FEMA), instruments issued to non-residents must be pure equity or compulsorily convertible. A standard US SAFE with optional conversion or redemption clauses is treated as unauthorized foreign debt, violating External Commercial Borrowing (ECB) guidelines. Such contraventions trigger RBI compounding proceedings that halt IPO approvals and institutional financing rounds.
7. How should deep-tech startups account for R&D expenditures under Ind AS 38?
Under Ind AS 38 (Intangible Assets), expenditures incurred during the initial “Research Phase” must be expensed immediately in the profit and loss statement. Once a project enters the “Development Phase” and demonstrates technical feasibility, commercial intent, and future economic benefit, costs can be capitalized as intangible assets under development. Maintaining clean accounting here is vital for IPO prospectus diligence.
8. What is the significance of clean Intellectual Property (IP) assignment deeds?
For deep-tech ventures, intellectual property constitutes the primary asset supporting enterprise value. If founders, university research labs, or external contract software engineers developed algorithms or hardware prototypes prior to formal incorporation without executing registered, stamped IP Assignment Deeds transferring all rights to the company, merchant bankers and SEBI will flag a fatal defect in asset title during IPO vetting.
9. How does an IGP listing impact cross-border “flipping” to Delaware or Singapore?
Historically, deep-tech founders executed corporate flips to foreign jurisdictions primarily to access foreign public markets (like NASDAQ) and specialized deep-tech venture funds. A functional, liquid IGP platform in India eliminates the necessity of flipping, allowing Indian founders to stay domestic, avoid onerous FEMA cross-border tax traps, and access sovereign Indian liquidity.
10. How does ComplianceGlobally prepare deep-tech startups for institutional IPO readiness?
ComplianceGlobally delivers institutional Virtual CFO and corporate governance infrastructure tailored for technology startups. We build audit-proof cap tables, structure FEMA-compliant CCPS/iSAFE instruments, manage Ind AS 38 R&D accounting hygiene, ensure complete IP assignment protection, and structure board governance to ensure deep-tech founders are IPO-ready from Day 1.
Build a Public-Market-Ready Deep-Tech Enterprise with ComplianceGlobally
Don’t wait for a Series B or an IPO roadshow to discover that your cap table, R&D accounting, or intellectual property assignment deeds are non-compliant. Whether you are building in semiconductors, space-tech, AI hardware, or biotechnology, ComplianceGlobally provides the institutional corporate governance and Virtual CFO architecture needed to prepare your startup for public market liquidity.
